Evidence map›Paper›PMID 39184056›Full record

ArticleACS bio & med chem Au2024

Selagibenzophenone B and Its Derivatives:

Serhat Dönmez, Ringaile Lapinskaite, Hazal Nazlican Atalay, Esra Tokay, Feray Kockar, Lukas Rycek, Mehmet Özbil, Tugba Boyunegmez Tumer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS bio & med chem Au, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Serhat DönmezGraduate Program of Molecular Biology and Genetics, School of Graduate Studies, Canakkale Onsekiz Mart University, Canakkale 17020, Turkey.ORCID https://orcid.org/0000-0002-6301-7243
Ringaile LapinskaiteDepartment of Organic Chemistry, Center for Physical Sciences and Technology (FTMC), Akademijos g. 7, Vilnius LT-08412, Lithuania.ORCID https://orcid.org/0000-0002-7865-9660
Hazal Nazlican AtalayGraduate Program of Molecular Biology and Genetics, School of Graduate Studies, Canakkale Onsekiz Mart University, Canakkale 17020, Turkey.
Esra TokayDepartment of Molecular Biology and Genetics, Faculty of Sciences and Arts, Balikesir University, Balikesir 10145, Turkey.
Feray KockarDepartment of Molecular Biology and Genetics, Faculty of Sciences and Arts, Balikesir University, Balikesir 10145, Turkey.
Lukas RycekDepartment of Organic Chemistry, Faculty of Science, Charles University, Hlavova 8, 128 43 Praha 2, Czechia.ORCID https://orcid.org/0000-0003-3028-8829
Mehmet ÖzbilInstitute of Biotechnology, Gebze Technical University, Kocaeli 41400, Turkey.
Tugba Boyunegmez TumerDepartment of Molecular Biology and Genetics, Faculty of Science, Canakkale Onsekiz Mart University, Canakkale 17020, Turkey.ORCID https://orcid.org/0000-0002-1740-4867

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of multitargeted drugs represents an innovative approach to cancer treatment, aiming to enhance drug effectiveness while minimizing side effects. Herein, we sought to elucidate the inhibitory effect of selagibenzophenone B derivatives on the survival of cancer cells and dual topoisomerase I/II enzyme activity. Results demonstrated that among the compounds,

Identifiers

PMID39184056
PMCPMC11342340

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.